• FDA presentation on Regulation of Allograft Heart Valves addresses the role of the OPTN and the FDA in partial heart transplant procedures
  Wednesday, April 17, 2024
  July 27, 2023 presentation clarifies FDA oversight authority.
  

• FDA presentation on Medical Device Reporting (MDR) Reporting Requirements
  Wednesday, April 17, 2024
  Feb. 5, 2024 presentation focused on required reporting of adverse events related to malfunctioning or defective medical devices.
  

• An important message from the MPSC on reporting Patient Safety events, DCD organ recovery pre-OR huddles, and other recommendations
  Monday, April 15, 2024
  The Membership and Professional Standards Committee shares opportunities for improvement with OPTN members.
  

• New pre-transplant performance metric to implement July 2024
  Monday, April 15, 2024
  The risk-adjusted metric is the third and the final phase of a comprehensive monitoring system.
  

• OPTN Executive Committee forms two work groups
  Monday, April 15, 2024
  Groups to make recommendations on OPTN code of conduct, project prioritization.
  

• An important message from the OPTN Board President on OPTN Board independence
  Tuesday, April 9, 2024
  OPTN Board of Directors and the OPTN continue to carry out its work and the patients it serves.
  

• Lung transplants for blood type O increase after modified blood type rating scale
  Monday, March 11, 2024
  Report captures three months of post implementation data.
  

• OPTN Expeditious Task Force town hall set for March 13
  Friday, March 8, 2024
  OPTN Expeditious Task Force town hall recording available.
  

• New OPTN board members elected for 2024
  Friday, March 8, 2024
  Terms begin July 1.
  

• White paper analyzes ethical issues in normothermic regional perfusion
  Friday, March 8, 2024
  Use of consistent and transparent protocols recommended.
  

Click on a page number to view more news in chronological order.